CD274 and ovarian cancer: The use of PD-L1 blockers reverses the inhibitory efficacy of PARPi on CD8 T cells, thereby enhancing the antitumor effects of PARPi [403], which also provides a theoretical basis for the combination therapy of PARPi and PD-L1 antibodies in ovarian cancer.